1,191
Participants
Start Date
August 28, 2019
Primary Completion Date
October 29, 2021
Study Completion Date
October 29, 2021
V114
15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F, serotype 6B and aluminum phosphate adjuvant in each 0.5 mL dose.
Prevenar 13™
13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, serotype 6B in each 0.5. mL dose.
Vaxelis™
Intramuscular 0.5 mL single dose
M-M-R®II
Subcutaneous 0.5 mL single dose
VARIVAX™
Subcutaneous 0.5 mL single dose
Hvidovre Hospital ( Site 0003), Hvidovre
Sykehuset i Vestfold ( Site 0063), Tønsberg
Stavanger universitetssykehus ( Site 0062), Stavanger
Odense Universitetshospital ( Site 0001), Odense C
Regionshospitalet Herning Hospitalsenheden Vest ( Site 0006), Herning
Aarhus Universitetshosp. Skejby ( Site 0002), Aarhus
Aalborg Universitetshospital ( Site 0005), Aalborg
Sygehus Vendsyssel Hjoerring ( Site 0004), Hjørring
IRCCS Ospedale Policlinico San Martino ( Site 0042), Genova
Turun rokotetutkimuskeskus ( Site 0026), Turku
Porin rokotetutkimusklinikka ( Site 0027), Pori
Tampereen yliopisto - Tampereen rokotetutkimusklinikka ( Site 0021), Tampere
Seinajoki Vaccine Research Center ( Site 0028), Seinäjoki
Kokkolan rokotetutkimusklinikka ( Site 0029), Kokkola
A.O. Policlinico Consorziale di Bari ( Site 0044), Bari
A.O.U. Riuniti Di Foggia - Igiene Universitaria ( Site 0046), Foggia
Tampereen yliopisto Oulun rokotetutkimusklinikka ( Site 0030), Oulu
Tampereen yliopisto Espoon rokotetutkimusklinikka ( Site 0024), Espoo
Tampereen yliopisto Etela-Helsingin Rokotetutkimusklinikka ( Site 0022), Helsinki
Tampereen yliopisto Ita-Helsingin rokotetutkimusklinikka ( Site 0023), Helsinki
Jarvenpaan rokotetutkimuskeskus ( Site 0025), Järvenpää
Policlinico Universitario Agostino Gemelli ( Site 0048), Rome
Oslo Universitetssykehus HF Ulleval Sykehus ( Site 0061), Oslo
Norrlands Universitetssjukhus ( Site 0100), Umeå
Merck Sharp & Dohme LLC
INDUSTRY